2 days ago
Yescarta Clinical Trial Results In the realm of medical advancements, few milestones have captivated the attention of oncologists and patients alike quite like the recent revelations from the Yesca...
2 days ago
Yescarta CD19: A Revolutionary CAR-T Therapy for Lymphoma In the realm of oncology, the development of targeted therapies has revolutionized the treatment landscape, offering new hope for patients ...
2 days ago
**Treatment for Multiple Myeloma: China’s BCMA×CD3 Bispecific Antibody Proposed for Breakthrough Therapy Designation** Multiple Myeloma #MultipleMyeloma #BCMAxCD3 #BispecificAntibody #Immunotherapy...
3 days ago
Yescarta (Axicabtagene Ciloleucel): A Groundbreaking CAR-T Therapy for Lymphoma Yescarta, also known as axicabtagene ciloleucel, is a revolutionary chimeric antigen receptor T-cell (CAR-T) therapy ...
3 days ago
Yescarta Approval Date and Indications Yescarta, a groundbreaking chimeric antigen receptor (CAR) T-cell therapy, has revolutionized the treatment landscape for certain types of lymphoma. This arti...
3 days ago
**Breakthrough Chinese Monoclonal ADC Targets Nectin-4: Achieving 91.9% Disease Control Rate Across Multiple Solid Tumors** Monoclonal ADC #MonoclonalADC #Nectin4 #Solidtumor #9MW2821 #cervicalcan...
4 days ago
Yescarta and Tecartus: Pioneering CAR-T Therapies for Lymphoma Treatment In the field of oncology, the advent of chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of c...
4 days ago
Yescarta and Kymriah In the rapidly evolving landscape of cancer immunotherapy, CAR-T (Chimeric Antigen Receptor T-cell) therapy has emerged as a game-changer, particularly for patients with certai...
4 days ago
China’s new drug Aumolertinib Mesilate Tablets: The world’s second EGFR-targeted therapy for lung cancer with gene mutations. lung cancer #LungCancer #EGFRInhibitor #TargetedTherapy #...
5 days ago
CAR-T Therapy in China: Relma-cel Offers Deep and Lasting Remission for Patients with Relapsed/Refractory Mantle Cell Lymphoma (MCL) MCL #MantleCellLymphoma #MCL #Lymphoma #RRMCL #RelmaCel #CART ...
6 days ago
China’s first BCMA CAR-T therapy successfully treats an overseas patient with advanced relapsed myeloma. 🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can su...
6 days ago
Yescarta 2L DLBCL Diffuse large B-cell lymphoma (DLBCL) is one of the most common and aggressive types of non-Hodgkin’s lymphoma, affecting thousands of adults worldwide each year. Despite ad...
By using our site, you agree to our Terms and Conditions and Privacy Policy.Advanced Medicine In China does not provide medical advice, diagnosis, or treatment. The information provided on this site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her existing physician.
© Copyright 2023 Advanced Medicine In China. All rights reserved.
